published meta-analysis   sensitivity analysis   studies

anakinra in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCORIMUNO-ANA-1, 2021 0.91 [0.38; 2.19] 0.91[0.38; 2.19]CORIMUNO-ANA-1, 202110%114NAnot evaluable deathsdetailed resultsCORIMUNO-ANA-1, 2021 0.97 [0.46; 2.04] SAVE-MORE, 2021 0.45 [0.20; 0.99] 0.67[0.31; 1.42]CORIMUNO-ANA-1, 2021, SAVE-MORE, 2021248%708moderatenot evaluable clinical deteriorationdetailed resultsCORIMUNO-ANA-1, 2021 0.89 [0.42; 1.92] SAVE-MORE, 2021 0.36 [0.26; 0.50] 0.53[0.22; 1.28]CORIMUNO-ANA-1, 2021, SAVE-MORE, 2021278%114lownot evaluable death or ventilationdetailed resultsCORIMUNO-ANA-1, 2021 0.97 [0.62; 1.52] 0.97[0.62; 1.52]CORIMUNO-ANA-1, 202110%116NAnot evaluable mechanical ventilationdetailed resultsSAVE-MORE, 2021 0.47 [0.03; 7.48] 0.47[0.03; 7.48]SAVE-MORE, 202110%594NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-03-29 11:06 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 652 - roots T: 290